# **ACCSYS H1 FY24 RESULTS**

For the six months ended 30 September 2023

**CHANGING WOOD TO CHANGE THE WORLD** 

21 November 2023





# **DISCLAIMER**

### NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION

No representation or warranty, express or implied, is made or given by or on behalf of Accsys Technologies PLC (the "Company" and, together with its subsidiaries and subsidiary undertakings, the "Group") or any of its directors or any other person as to the accuracy, completeness or fairness of the information contained in this presentation and no responsibility or liability is accepted for any such information.

This presentation may contain 'forward-looking statements' with respect to certain of the Group's plans and its current goals and expectations relating to its future financial condition, performance, results, strategic initiatives and objectives. Generally, words such as "may", "could", "will", "expect", "intend", "estimate", "anticipate", "aim", "outlook", "believe", "plan", "seek", "continue" or similar expressions identify forward-looking statements.

These forward-looking statements are not guarantees of future performance. By their nature, all forward-looking statements involve risk and uncertainty because they relate to future events and circumstances which are beyond the Group's control, including amongst other things, UK domestic and global economic business conditions, market-related risks such as fluctuations in interest rates and exchange rates, the policies and actions of regulatory authorities, the impact of competition, inflation, deflation, the timing impact and other uncertainties of future acquisitions or combinations within relevant industries, as well as the impact of tax and other legislation or regulations in the jurisdictions in which the Group and its affiliates operate.

As a result, the Group's actual future financial condition, performance and results may differ materially from the plans, goals and expectations set forth in the Group's forward-looking statements. Forward-looking statements in this presentation are current only as of the date on which such statements are made. The Group undertakes no obligation to update any forward-looking statements, save in respect of any requirement under applicable law or regulation. Nothing in this presentation is intended to be, or intended to be construed as, a profit forecast or a guide as to the performance, financial or otherwise, of the Company or the Group whether in the current or any future financial year.

Nothing in this presentation should be construed as either an offer to sell or a solicitation of an offer to buy or sell the Company's securities in any jurisdiction, or be treated or relied upon as a recommendation or advice by the Company. This presentation and its contents should not be distributed, published or reproduced (in whole or in part) or disclosed by recipients to any other person.

The views expressed in this presentation contain certain information which has been derived from publicly available sources that have not been independently verified. No representation or warranty is made as to the accuracy, completeness or reliability of such information.

21 NOVEMBER 2023



# **FINANCIAL HIGHLIGHTS**

	€million	H1 FY24	H1 FY23	Change %
FINANCIAL SUMMARY	Group Revenue  Gross Profit  Underlving operating costs  Underlving EBITDA  Exceptional item - Restructuring cost	71.2 20.3 (17.7) 1.6 (1.2)	58.9 18.1 (13.3) 4.5	21% 12% (33%) (64%)
FINA	Non-cash exceptional item - Impairment of Tricoya Segment assets	(7.0)	(58.0)	-
CASHFLOW	Net debt <sup>4</sup> Adjusted cash <sup>5</sup>	(48.2) 10.8	(61.4) 7.2	
PRODUCT	Accoya sales volume (m <sup>3</sup> ) Group Gross Marcin	28.807 29%	23.957 31 %	20% (2%)

<sup>&</sup>lt;sup>1.</sup> Underlying operating costs exclude Depreciation and Amortisation. <sup>2.</sup> Underlying results include Accsys share of results relating to Accoya USA JV. <sup>3.</sup> Other exceptional items recognised in the prior year (H1 FY23) include €0.5m related to advisor fees related to the Tricoya consortium reorganisation <sup>4.</sup> Net debt at 31 March 2023 was €44.1m <sup>5.</sup> Adjusted cash excludes cash pledged for the Letter of Credit provided to FHB.

21% growth in Group Revenue







	H1 FY24	Growth
Revenue	€68.2m	+16%
Sales volumes	28,807m <sup>3</sup>	+20%

Sales volume by end market	H1 FY24 m <sup>3</sup>	Growth
UK & Ireland	6,165	+6%
Rest of Europe	7,385	+28%
North America	4,218	+4%
Rest of World	2,646	+42%
Tricoya®	8,393	+30%

- Revenues up 16% to €68.2m, driven by good product demand and increased production capacity following Reactor 4 commercial startup in September 2022
- 20% growth in Accoya sales volumes in H1
- Particularly strong performances from Rest of World (+42%) and Rest of Europe (+28%)
- 30% growth in Accoya for Tricoya production, supporting our belief in Tricoya market potential
- Good customer demand as customers seek products that deliver outstanding performance, durability and sustainability

33% additional capacity in Arnhem plant following start-up of fourth reactor in September 2022.



# TRICOYA H1 FY24 PERFORMANCE



	H1 FY24	Growth
Revenue	€11.4m	+31%
Sales volumes	8,393m <sup>3</sup>	+30%




- Revenues from Tricoya represent 29% of total Group sales volumes
- H1 FY24 revenues up 31% to €11.4m, driven by continued strong product demand:
  - Off-take partners MEDITE and FINSA remain committed and supportive

30% growth in sales volumes of Tricoya, reinforces our belief in the long-term market potential of Tricoya.



# EBITDA SEGMENTAL BREAKDOWN

Group underlying EBITDA (€ million)



- Continued strong operational performance from the Accoya segment (excl. Accoya USA)
- Accoya USA represents preoperating costs as project progresses to commercial start-up
- Tricoya EBITDA reflects its preoperating position – remains in hold period
- Restructuring cost (exceptional item) of €1.2m in relation to organisational re-alignment and cost savings initiatives – to deliver annual cost savings of €3.0m+



# **EBITDA PROGRESSION IN H1 FY24**




#### 12% increase in Gross profit (€2.2m)

- Higher average Accoya sales prices
- 20% increase in Accoya sales volume
- Raw material costs:
  - Net acetyls cost decreased vs PY
  - Offset by moderately higher wood pricing and higher wood mix cost as raw material levels lowered
- Increased pre-operating and operating costs (€2.7m)
  - Tricoya €2.0m decrease in costs capitalised due to project in hold period
  - Accoya USA €0.7m increase in pre-operating costs as project progresses to commercial start-up
  - Increase in other opex due to higher sales & marketing, executive recruitment and engineering costs




# **NET DEBT BRIDGE**




Other movements include tax received, investment in intangible assets, interest received, other operating cash flows and other financing costs.



# FIVE-YEAR VOLUME & REVENUE PERFORMANCE



• New reactor 4 in Arnhem operational from September 2022



Accoya USA plant operational in mid-2024



# **CURRENT TRADING & OUTLOOK**

### **Current Trading**

### **Outlook for H2 FY24**

- Trading continues to be challenging, reflecting difficult macro conditions across our markets; sales performance by region remains mixed
- Volumes remain under pressure as distributors reduce inventory ahead of upcoming holiday period
- Despite ongoing difficult market conditions, we have maintained our premium price point on both Accoya and Tricoya, reflecting the durability, sustainability and high-performance attributes of both products

- Trading conditions not expected to materially improve until mid-2024, which is likely to place some pressure on sales in the near term
- Accsys' financial performance is typically second-half weighted, reflecting higher sales levels in January to March in anticipation of summer construction projects
- Further improvement in product demand anticipated in Q4 following destocking unwind by existing distributors and strong opening stock commitments from new distributors
- In addition, the Company continues to take self-help actions to manage working capital and reduce costs
- Given the current market backdrop and expected sales volume for the remainder of this financial year, the Board believes that the FY24 results will be below current market expectations.



# **FUNDRAISE**

### Fundraise – raising €24m Gross new proceeds

- Announced today
- Equity placing of up to approximately €13m to €15m
  - Fixed price of 69.35 Euro cents through accelerated bookbuild
  - Expected to represent in aggregate between approximately 8.6% and approximately 9.8% of the Company's share capital
- Convertible loan notes
  - o Issue of between €9.0m €11m new Convertible Ioan notes
  - Refinance of existing 2022 €10m Convertible loan note on same terms
  - o Terms:
    - Six-year term
    - Fixed rate of 9.5% Rolled up for first 2.5 years, deferred and paid over remaining 3.5 years
    - Holders have right to convert at of 83.22 Euro cents per share
    - Unsecured, not transferable
    - No covenants

#### **ABN Debt Refinance**

- Refinance of €40.5m Term Loan & €25m RCF:
  - o Extended by 18 months to 31 March 2026
  - Release of €10m cash collateral, €7.5m used to repay portion of Term loan, €2.5m available for general liquidity purposes
  - Repayment holiday to July 2025, quarterly payments of €1.125m thereafter
  - o Borrowings costs:
    - Term loan 4.34% 5.34%
    - RCF Margin of 3% 4% over Euribor
  - Financials covenants remained the same except for Net Debt/EBITDA increasing to 2.75x for three quarters
- ABN Refinance conditional on the Company raising €24m through fundraise



# **FUNDRAISE - USE OF PROCEEDS**

#### Allows delivery of US JV plant, operational improvements and a strengthened balance sheet

New funding use of proceeds	Rationale	Quantum (approx.)
US JV	Completion of construction	c.€15.5m
US JV	Funding required to support initial losses and ramp-up in operations	c.€6.5m
General Working Capital	Additional funding for general working capital purposes	c.€2m
Total		c.€24m

~€22 million to be used to fund Accsys's share of the US JV US JV – completion of construction

- US plant progressing well
  - o Construction ~ 78% complete,
  - o Equipment settings ~ 87% complete
- Total construction cost for the US plant is now expected to be approximately \$160 million, reflecting a more realistic build cost schedule and construction cost inflation

### **Expected timetable\***

Announce interim results and launch fundraise	21 Nov (7am)
Close fundraise and sign-off allocations	21 Nov (intraday)

